Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic SyndromesMaria Teresa Voso, Giuseppe Leone, Valeria Santini et al.|Clinical Cancer Research|2009Cited by 101
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective studyMaria Teresa Voso, Simona Sica, Giuseppe Leone et al.|Annals of Oncology|2017Cited by 57
Molecular and clinical presentation of <i>UBA1</i>-mutated myelodysplastic syndromesMaria Sirenko, Joop H. Jansen, Birgitta Sander et al.|Blood|2024Cited by 53
Quality of life and physicians' perception in myelodysplastic syndromes.Oliva En, Spiriti Ma, Carlo Finelli et al.|PubMed|2012Cited by 51
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacyEsther Natalie Olíva, Maria Antonietta Aloe Spiriti, Roberto Latagliata et al.|Leukemia & lymphoma/Leukemia and lymphoma|2013Cited by 30